Abstract: FR-PO0210
Effect of Roxadustat on Microinflammatory Status in Patients with CKD
Session Information
- CKD: Mechanisms of Injury and Fibrosis - 2
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2203 CKD (Non-Dialysis): Mechanisms
Authors
- Ke, Yixi, Southern University of Science and Technology School of Medicine, Shenzhen, Guangdong, China
- Ma, Hualin, Shenzhen People's Hospital Department of Nephrology, Shenzhen, Guangdong, China
Background
Roxadustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has demonstrated multifaceted benefits in treating anemia of chronic kidney disease (CKD), yet the precise mechanism underlying its anti-inflammatory effects remains unclear. This study aimed to investigate the associated mechanisms from the perspective of the metabolism-inflammation axis.
Methods
This study integrated untargeted metabolomics, in vitro validation, and clinical cohort analysis. Serum from six CKD stage 3-5 patients with anemia was collected before and after roxadustat treatment for metabolomic profiling to identify differential metabolites. The candidate metabolite, cyclopentolate, was used to stimulate human renal tubular epithelial cells, assessing inflammatory factor changes and the modulatory effect of roxadustat. Finally, key inflammatory factors were quantified in an independent validation cohort of 30 CKD patients before and after treatment.
Results
Metabolomic profiling revealed that roxadustat treatment significantly altered the expression of 4,516 serum metabolites. In vitro, cyclopentolate stimulation markedly upregulated inflammatory factors (TNF-α, IL-6, MIP-1α, GROα, Eotaxin-1), an effect that was effectively reversed by roxadustat co-treatment (all P<0.001). Clinical validation confirmed that serum levels of these specific inflammatory factors were all significantly downregulated following roxadustat treatment in the independent cohort (all P<0.05).
Conclusion
Roxadustat may exert renoprotective effects by modulating the metabolism-inflammation network, providing novel insights into its pleiotropic benefits in the treatment of CKD-associated anemia.
Funding
- Government Support – Non-U.S.